Background: Clinical relevance of tumor infiltrating lymphocytes (TILs) in breast cancer is controversial. Here, we used a tumor microarray including a large series of ductal and lobular breast cancers with long term follow up data, to analyze clinical impact of TIL expressing specific phenotypes and distribution of TILs within different tumor compartments and in different histological subtypes.Methods: A tissue microarray (TMA) including 894 ductal and 164 lobular breast cancers was stained with antibodies recognizing CD4, FOXP3, and IL-17 by standard immunohistochemical techniques. Lymphocyte counts were correlated with clinico-pathological parameters and survival.Results: CD4+lymphocytes were more prevalent than FOXP3+TILs whereas IL-17+TILs were rare. Increased numbers of total CD4+and FOXP3+TIL were observed in ductal, as compared with lobular carcinomas. High grade (G3) and estrogen receptor (ER) negative ductal carcinomas displayed significantly (p< 0.001) higher CD4+and FOXP3+lymphocyte infiltration while her2/neu over-expression in ductal carcinomas was significantly (p< 0.001) associated with higher FOXP3+TIL counts. In contrast, lymphocyte infiltration was not linked to any clinico-pathological parameters in lobular cancers. In univariate but not in multivariate analysis CD4+infiltration was associated with significantly shorter survival in patients bearing ductal, but not lobular cancers. However, a FOXP3+/CD4+ratio > 1 was associated with improved overall survival even in multivariate analysis (p= 0.033).Conclusions: Ductal and lobular breast cancers appear to be infiltrated by different lymphocyte subpopulations. In ductal cancers increased CD4+and FOXP3+TIL numbers are associated with more aggressive tumor features. In survival analysis, absolute numbers of TILs do not represent major prognostic indicators in ductal and lobular breast cancer. Remarkably however, a ratio > 1 of total FOXP3+/CD4+TILs in ductal carcinoma appears to represent an independent favorable prognostic factor.
Production of indoleamine 2,3‐dioxygenase (IDO) by tumor cells, leading to tryptophan depletion and production of immunosuppressive metabolites, may facilitate immune tolerance of cancer. IDO gene is also expressed in dendritic cells (DC) upon maturation induced by lipopolysaccarides or IFN. We investigated IDO gene expression in melanoma cell lines and clinical specimens as compared to mature DC (mDC). Furthermore, we explored effects of L‐kynurenine (L‐kyn) and 3‐hydroxyanthranilic acid (3‐HAA) on survival and antigen‐dependent and independent proliferation of CD8+ cells. We observed that IDO gene expression in cultured tumor cells and freshly excised samples is orders of magnitude lower than in mDC, providing highly efficient antigen presentation to CD8+ T cells. Non toxic concentrations of L‐kyn or 3‐HAA did not significantly inhibit antigen‐specific CTL responses. However, 3‐HAA, but not L‐kyn markedly inhibited antigen‐independent proliferation of CD8+ T cells induced by common receptor γ‐chain cytokines IL‐2, ‐7 and ‐15. Our data suggest that CD8+ T cell activation induced by antigenic stimulation, a function exquisitely fulfilled by mDC, is unaffected by tryptophan metabolites. Instead, in the absence of effective T cell receptor triggering, 3‐HAA profoundly affects homeostatic proliferation of CD8+ T cells.
26 September 2011 in Journal of Translational Medicine
Chronic inflammation has been suggested to favour prostate cancer (PCA) development. Interleukins (IL) represent essential inflammation mediators. IL-2, IL-7, IL-15 and IL-21, sharing a common receptor γ chain (c-γ), control T lymphocyte homeostasis and proliferation and play major roles in regulating cancer-immune system interactions. We evaluated local IL-2, IL-7, IL-15 and IL-21 gene expression in prostate tissues from patients with early stage PCA or benign prostatic hyperplasia (BPH). As control, we used IL-6 gene, encoding an IL involved in PCA progression. IL-6, IL-7 and IL-15 titres were also measured in patients' sera.
Non small cell lung cancers (NSCLC) express cancer/testis antigens (CTA) genes and MAGE‐A expression correlates with poor prognosis in squamous cell carcinomas. We addressed cytotoxic T lymphocytes (CTL) responses to HLA class I restricted CTA epitopes in TIL from NSCLC in an unselected group of 33 patients consecutively undergoing surgery. Expression of MAGE‐A1, ‐A2, ‐A3, ‐A4, ‐A10, ‐A12 and NY‐ESO‐1 CTA genes was tested by quantitative RT‐PCR. Monoclonal antibodies (MAb) recognizing MAGE‐A and NY‐ESO‐1 CTA were used to detect CTA by immunohistochemistry. CD8+ TIL obtained from tumors upon culture with anti CD3 and anti CD28 mAb and IL‐2 were stimulated with autologous mature DC (mDC) and HLA‐A*0101 restricted MAGE‐A1161–169 or MAGE‐A3168–176 peptides or HLA‐A*0201 restricted MAGE‐A4230–239, MAGE‐A10254–262, NY‐ESO‐1157–165 or multi‐MAGE‐A (YLEYRQVPV) peptides or a recombinant vaccinia virus (rVV) encoding MAGE‐A and NY‐ESO‐1 HLA‐A*0201 restricted epitopes and CD80 co‐stimulatory molecule. Specificity was assessed by 51Cr release and multimer staining. At least one CTA gene was expressed in tumors from 15/33 patients. In 10 specimens, at least 4 CTA genes were concomitantly expressed. These data were largely confirmed by immunohistochemistry. TIL were expanded from 26/33 specimens and CTA‐specific CTL activity was detectable in 7/26 TIL. In 6, however, specific cytotoxicity was weak, (60% lysis at 50:1 E:T ratio) MAGE‐A10254–262 specific, HLA‐A*0201 restricted response was observed. Supportive evidence was provided by corresponding multimer staining. Although CTA genes are frequently expressed in NSCLC, detection of CTL reactivity against CTA epitopes in TIL from nonimmunized NSCLC patients represents a rare event.